Compare VENUS REMEDIES with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES PROCTER & GAMBLE HEALTH VENUS REMEDIES/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x -1.0 53.0 - View Chart
P/BV x 0.1 4.6 1.6% View Chart
Dividend Yield % 0.0 10.3 -  

Financials

 VENUS REMEDIES   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
VENUS REMEDIES/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1263,549 3.5%   
Low Rs611,301 4.7%   
Sales per share (Unadj.) Rs301.8511.4 59.0%  
Earnings per share (Unadj.) Rs-24.961.3 -40.6%  
Cash flow per share (Unadj.) Rs2.574.0 3.4%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs293.3927.8 31.6%  
Shares outstanding (eoy) m12.3416.60 74.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.7 6.5%   
Avg P/E ratio x-3.839.6 -9.5%  
P/CF ratio (eoy) x36.732.8 112.1%  
Price / Book Value ratio x0.32.6 12.2%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m1,15440,257 2.9%   
No. of employees `0000.91.1 81.6%   
Total wages/salary Rs m3931,313 29.9%   
Avg. sales/employee Rs Th4,026.17,486.7 53.8%   
Avg. wages/employee Rs Th425.01,157.6 36.7%   
Avg. net profit/employee Rs Th-331.8897.2 -37.0%   
INCOME DATA
Net Sales Rs m3,7248,490 43.9%  
Other income Rs m23244 9.2%   
Total revenues Rs m3,7478,734 42.9%   
Gross profit Rs m3951,482 26.6%  
Depreciation Rs m338211 160.2%   
Interest Rs m3540-   
Profit before tax Rs m-2751,514 -18.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m32563 5.6%   
Profit after tax Rs m-3071,017 -30.2%  
Gross profit margin %10.617.5 60.7%  
Effective tax rate %-11.537.1 -30.9%   
Net profit margin %-8.212.0 -68.8%  
BALANCE SHEET DATA
Current assets Rs m2,63815,343 17.2%   
Current liabilities Rs m2,3051,960 117.6%   
Net working cap to sales %8.9157.6 5.7%  
Current ratio x1.17.8 14.6%  
Inventory Days Days13549 277.9%  
Debtors Days Days4628 162.9%  
Net fixed assets Rs m4,8711,209 402.8%   
Share capital Rs m123166 74.3%   
"Free" reserves Rs m3,49615,235 22.9%   
Net worth Rs m3,61915,401 23.5%   
Long term debt Rs m1,3740-   
Total assets Rs m7,50917,595 42.7%  
Interest coverage x0.2NM-  
Debt to equity ratio x0.40-  
Sales to assets ratio x0.50.5 102.8%   
Return on assets %0.65.8 10.9%  
Return on equity %-8.56.6 -128.4%  
Return on capital %1.610.3 15.4%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m01,636 0.0%   
Fx outflow Rs m5174,368 11.8%   
Net fx Rs m-517-2,732 18.9%   
CASH FLOW
From Operations Rs m514-1,304 -39.5%  
From Investments Rs m-12312,697 -1.0%  
From Financial Activity Rs m-387-301 128.8%  
Net Cashflow Rs m411,093 0.0%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 0.2 18.2 1.0%  
FIIs % 0.6 1.0 58.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 29.1 228.2%  
Shareholders   20,121 28,591 70.4%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   CADILA HEALTHCARE  FDC LTD.  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare VENUS REMEDIES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 76 Points Lower; Telecom and Metal Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their volatile day marginally lower.

Related Views on News

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH 2017-18 Annual Report Analysis (Annual Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

Here's an analysis of the annual report of PROCTER & GAMBLE HEALTH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PROCTER & GAMBLE HEALTH. Also includes updates on the valuation of PROCTER & GAMBLE HEALTH.

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

More Views on News

Most Popular

The Smartest Stock to Buy for 2020(Profit Hunter)

Nov 14, 2019

Small-cap stocks are selling at bargain prices today and are poised to generate a lot of wealth in 2020 and beyond...

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

The One Trade I'm Most Bullish on Now

Nov 12, 2019

A highly specific trade to potentially triple your money in just three months. You won't find this information anywhere else!

How the Modi Government is Helping My Top 7 Stocks(The 5 Minute Wrapup)

Nov 14, 2019

Recent reforms by the Modi government can give a big boost on your stocks, provided you buy the right ones.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Nov 21, 2019 03:37 PM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS